The findings indicated that PSME1 expression level may affect the prognosis of GC patients, partly because it impacts the degree of immune infiltration, and that PSME1 could act as a potential biomarker for the response to immunotherapy of GC patients. Here, PSME1 is linked to gastric cancer.